Patents by Inventor Mike Gabrin

Mike Gabrin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR SELECTING ACTIVE AGENTS FOR CANCER TREATMENT
    Publication number: 20120219982
    Abstract: The present invention provides methods for individualizing chemotherapy, and particularly methods for individualizing neoadjuvant chemotherapy. The present invention provides methods for predicting a cancer patient's response to neoadjuvant chemotherapy, including assessing the probability of a positive response upon treatment with candidate agents prior to surgery. In various aspects, the invention involves culturing a monolayer of malignant cells from an explant of a patient's biopsy specimen, such as a transcutaneous biopsy-sized specimen, and testing the malignant cells for resistance or sensitivity to one or a plurality of candidate agents for neoadjuvant therapy. In other aspects, the invention provides methods for accurately scoring and interpreting such assays, and discloses in vitro chemoresponse results that are predictive of a patient's pathological complete response (pCR) upon receiving the corresponding treatment regimen.
    Type: Application
    Filed: May 1, 2012
    Publication date: August 30, 2012
    Applicant: Precision Therapeutics, Inc.
    Inventors: Zhibao Mi, Dave Gingrich, Mike Gabrin
  • Methods for selecting active agents for cancer treatment
    Patent number: 8187800
    Abstract: The present invention provides methods for individualizing chemotherapy, and particularly methods for individualizing neoadjuvant chemotherapy. The present invention provides methods for predicting a cancer patient's response to neoadjuvant chemotherapy, including assessing the probability of a positive response upon treatment with candidate agents prior to surgery. In various aspects, the invention involves culturing a monolayer of malignant cells from an explant of a patient's biopsy specimen, such as a transcutaneous biopsy-sized specimen, and testing the malignant cells for resistance or sensitivity to one or a plurality of candidate agents for neoadjuvant therapy. In other aspects, the invention provides methods for accurately scoring and interpreting such assays, and discloses in vitro chemoresponse results that are predictive of a patient's pathological complete response (pCR) upon receiving the corresponding treatment regimen.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: May 29, 2012
    Assignee: Precision Therapeutics, Inc.
    Inventors: Zhibao Mi, Dave Gingrich, Mike Gabrin
  • METHODS FOR SELECTING ACTIVE AGENTS FOR CANCER TREATMENT
    Publication number: 20090104647
    Abstract: The present invention provides methods for individualizing chemotherapy, and particularly methods for individualizing neoadjuvant chemotherapy. The present invention provides methods for predicting a cancer patient's response to neoadjuvant chemotherapy, including assessing the probability of a positive response upon treatment with candidate agents prior to surgery. In various aspects, the invention involves culturing a monolayer of malignant cells from an explant of a patient's biopsy specimen, such as a transcutaneous biopsy-sized specimen, and testing the malignant cells for resistance or sensitivity to one or a plurality of candidate agents for neoadjuvant therapy. In other aspects, the invention provides methods for accurately scoring and interpreting such assays, and discloses in vitro chemoresponse results that are predictive of a patient's pathological complete response (pCR) upon receiving the corresponding treatment regimen.
    Type: Application
    Filed: October 15, 2008
    Publication date: April 23, 2009
    Inventors: Zhibao Mi, Dave Gingrich, Mike Gabrin